Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis

Fig. 3

Subgroup analyses according to combination regimens. a Pooled analysis of overall survival (OS). b Pooled analysis of progression-free survival (PFS). c Pooled analysis of objective response rate (ORR). IRI, irinotecan; Ox, oxaliplatin; MTAs, molecular targeting agents; CapOx, capecitabine plus oxaliplatin; C-mab, cetuximab; 5-FU, 5-fluorouracil; FPs, fluoropyrimidines; EGFR, epidermal growth factor receptor; and VEGF, vascular endothelial growth factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us